Compare Apple Inc (AAPL) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs Pfizer Inc — how do they compare? Apple Inc trades at $305.1 (market cap $4.50T), while Pfizer Inc trades at $26.59 (market cap $154.18B). The key difference: Apple Inc is far larger — about 29.2× Pfizer Inc's market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.
| AAPL | PFE | |
|---|---|---|
Market Cap | $4.50T | $154.18B |
Volume | 100,358,844 | 29,869,932 |
Sector | Technology | Health |
52-Week High | $340.08 | $28.56 |
52-Week Low | $224.90 | $23.60 |
Enterprise Value | $4.52T | $205.67B |
Dividend Yield | 0.35% | 6.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal but strong fundamentals including a 26.91% net margin and three consecutive quarterly EPS beats. Recent news highlights AI potential via 2.5 billion devices and a Gemini partnership, though store closures and union disputes present headwinds.
The outlook balances robust earnings growth and cash flow against high valuation multiples and technical weakness. Upside to the $337.63 consensus target exists if AI initiatives accelerate, but competition and macroeconomic pressures remain key risks for investors.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
